ALK101sc / Allink Biotherapeutics - LARVOL DELTA

ALK101sc, a novel afucosylated bispecific antibody targeting EGFR and c-MET with common light chain demonstrates potent, broad-spectrum antitumor activity (AACR 2026) - "Furthermore, combining ALK101sc with osimertinib produced synergistic antitumor efficacy, even in the presence of TKI‑insensitive mutations...Moreover, its CLC-based design provides a streamlined CMC development pathway, positioning it as a promising therapeutic candidate for overcoming EGFR TKI resistance. Compared with intravenous formulations, subcutaneous ALK101sc can substantially reduce administration time, improve patient convenience, and is expected to have a more favorable safety profile—characterized by meaningful reductions in infusion‑related reactions (IRR) and venous thromboembolism (VTE) rates."

Bispecific • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • EGFR • HGF • MET